Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform.

Financial terms and therapeutic focus of Monday’s deal are undisclosed. Prism BioLab Co. Ltd. will screen its library of peptide mimetic small molecules against targets chosen by Boehringer Ingelheim GmbH, which has options to license and develop any resulting compounds...